Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roivant Sciences posts presentation on FDA approval and launches LISRAYA commercially ...

29 August 2026 · By · Wire by Fusion42

Published

29 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

Roivant Sciences announced FDA approval of LISRAYA (brepocitinib) for adult dermatomyositis and launched the drug commercially at a wholesale acquisition cost of $35,000 per 30-count bottle, with prescribing now open and patient support active.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 28 Aug 2026 and 29 Aug 2026.

◆ ◆ The Wire takeaway

You must prepare to navigate payer negotiations and patient access at launch price point to maximise LISRAYA uptake. Specialty pharmacies and support services now form the main channel to reach prescribers and patients in dermatomyositis.

◆ Coverage

2 sources · first reported 28 Aug 2026 · latest 29 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaldrug-launchdermatomyositispharma-pricingspecialty-pharmacy